Karuna Therapeutics, Inc.·4

Nov 30, 5:12 PM ET

Lykins Charmaine 4

4 · Karuna Therapeutics, Inc. · Filed Nov 30, 2021

Insider Transaction Report

Form 4
Period: 2021-11-29
Lykins Charmaine
Chief Commercial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2021-11-29+75,00075,000 total
    Exercise: $125.52Exp: 2031-11-28Common Stock (75,000 underlying)
Footnotes (1)
  • [F1]25% of this option shall vest on November 29, 2022, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION